NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Tetraneuron

Tetraneuron

Private
MadridHealthcare & Life Scienceshttps://tetraneuron.com/en/

Last Round

VC Round

Dec 9, 2025

Total Funding Raised

$5.31M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Tetraneuron is a biotechnology company that develops AAV-based gene therapies to treat Alzheimer's disease and other neurodegenerative disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyneurodegenerative diseaseAlzheimer's treatmentAAV9biotechdrug discoveryprecision medicinebiotech licensingneuronal homeostasisE2F4clinical stage biotechbiotech startuptherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tetraneuron Comparables

Compare Tetraneuron with similar companies based on industry and business-model similarity.

Tetraneuron comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
LEXEO Therapeutics
77%
VectorY Therapeutics
74%
AviadoBio
74%

Tetraneuron Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundDec 9, 2025
SeedDec 27, 2022

Key People

Founding team and executive leadership

Angel Lucio

Chief Executive Officer, Board Member and Seed Investor

Executive Team

Tetraneuron Investors

Notable investors and investment history

Tetraneuron investors
InvestorRounds
GIMIC VenturesVC Round
Johnson & Johnson Innovation - JLABSSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 16, 2026

    Grew 25% QoQ, from 16 to 20 employees.

  • Dec 9, 2025

    Raised $5.85M led by GIMIC Ventures

Tetraneuron Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Tetraneuron Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Tetraneuron's valuation, stock price, and market status.

Firmographic Details

HeadquartersMadrid
Employee Range20
Year Founded2012
Last FundingDec 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.